It could be AMGN just soured on the whole personalized cancer route given the underlying manufacturing/scaling/COG hurdles. In fact they do seem to be prioritizing bispecifics like Roche and Regeneron, although they do have an early CAR-T asset too. So assuming it was more of a strategic decision to drop ADXS (although I still think the timing is odd), and not some safety or manufacturing issue at play, then if the drug is (re) partner-able a company like GILD or NVS or even whoever has provenge now (I can't keep track) - i.e. someone w existing manufacturing/commercial infrastructure and dedication to personalized therapy would probably be the best fit as a partner Just spitballing here from the sidelines
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.